PE-22-28 Reconstitution Calculator

No. PE-22-28 is a shortened spadin analog studied preclinically; no primary molecular target established, but it is proposed to act as a TREK-1 potassium channel inhibitor, with antidepressant-like and neuroplasticity-related effects in rodents; the corpus does not include human clinical trials, approval data, or labeled medical use (animal).

PE-22-28 is designed to inhibit the TREK-1 channel, though no primary molecular target established, a target linked to depression-related signaling; in hTREK-1/HEK cells it showed markedly higher affinity than the parent peptide spadin, with reported IC50 around 0.12 nM versus 40-60 nM for spadin (in-vitro). In mice, PE-22-28 reduced immobility in forced-swim testing, lowered latency in novelty-suppressed feeding after 4-day treatment, increased cortical PSD-95 expression, and promoted hippocampal neurogenesis, consistent with antidepressant-like and neuroplasticity effects rather than classic acute stimulant effects (animal).

The evidence base is for peptide administration in preclinical work, not oral use; practical use is therefore generally by subcutaneous injection (community protocol). The cited study evaluated in vivo antidepressant-like effects and duration after administration but does not establish an oral human dosing method, and small peptides like this are generally expected to have poor oral bioavailability without formulation support (mechanistic/community protocol).

There is no human dose established in the corpus. In practice, research users commonly discuss PE-22-28 in low-microgram ranges by subcutaneous injection, often once daily, sometimes split, for short exploratory cycles of 2-6 weeks (community protocol). Because the published evidence is animal and potency at TREK-1 is high, practitioner consensus usually starts low rather than extrapolating aggressively from other peptides (practitioner consensus).

PE-22-28 appears longer-acting than spadin in preclinical work. The paper reports that spadin activity disappeared beyond 7 hours, whereas PE-22-28 and analogs showed action duration improved up to 23 hours, supporting roughly once-daily exposure as the most plausible practical schedule (animal).

If the peptide translates as expected, it is usually discussed as faster-acting than conventional antidepressants because preclinical behavioral effects, neurogenesis, and synaptogenesis signals were seen after only 4 days of treatment in mice (animal). That does not prove the same onset in humans; for real-world experimentation, users typically judge response over 1-2 weeks rather than a single dose (community protocol).

PE-22-28 is essentially a shorter, optimized spadin-derived sequence. Compared with spadin, it showed stronger TREK-1 inhibition, retained antidepressant-like activity, improved in vivo duration, and supported neurogenesis/synaptogenesis in mice, making it the more pharmacologically attractive analog in this lineage (in-vitro/animal). The tradeoff is that all of this remains preclinical, so “better” means better in animal/pharmacology terms, not clinically proven superiority in humans.

There are no human interaction studies in the corpus. Mechanistically, PE-22-28 acts through TREK-1 inhibition rather than directly through monoamine reuptake, so overlap with SSRIs/SNRIs is not identical (mechanistic). In practice, users who combine it with prescription antidepressants, ketamine, or other psychoactive agents generally do so cautiously and one variable at a time, because onset, anxiety activation, sleep changes, or mood destabilization are the main practical concerns (practitioner consensus).

The corpus does not provide a formal human adverse-effect profile. Based on its CNS activity and antidepressant-like pharmacology, the most plausible practical issues are stimulation, altered sleep, irritability, headache, nausea, or injection-site irritation (mechanistic/community protocol). Because PE-22-28 enhanced neuroplasticity-related markers and produced behavioral effects in mice, users with bipolar-spectrum illness or strong anxiety sensitivity are usually considered higher-risk groups for mood activation (practitioner consensus).

There is no pregnancy, fertility, lactation, or developmental safety dataset in the corpus for PE-22-28. Because the compound has central nervous system activity and only animal efficacy data are available, it is generally avoided in pregnancy and breastfeeding unless future human safety data emerge (animal/mechanistic).

For practical handling, lyophilized peptide is usually kept cool, dry, and protected from light; once reconstituted, refrigeration is standard and shorter-use windows are preferred (community protocol). For travel, insulated cold packs are commonly used for reconstituted vials, while unopened lyophilized vials are easier to transport; users should carry labeled supplies and follow airline rules for injectables (community protocol).